Bone Bank Allografts Becomes First Tissue Bank to Select the Recently-Launched Clearant Sterilization Service.

LOS ANGELES -- Clearant, Inc. (OTCBB: CLRI), the developer of the patent-protected CLEARANT PROCESS(R) for pathogen inactivation, announced today that Bone Bank Allografts, a leading tissue bank, has become the first company to select the Clearant Sterilization Service for its tissue sterilization needs. Bone Bank Allografts, which distributes 30,000 allografts annually, will utilize Clearant's Sterilization Service on a variety of human-sourced bone and connective soft-tissue allograft implants. The Clearant Sterilization Service, which was launched earlier this month, is a complementary offering to the CLEARANT PROCESS(R) for tissue banks, allowing use of Clearant's technology on a pay-per-order basis.

"Based on my previous experience with utilizing the CLEARANT PROCESS(R), I am confident Bone Bank Allografts' clients will benefit from the higher sterility assurance levels associated with this special tissue sterilization process," said John Lee, COO of Bone Bank Allografts. "Clearant's innovative business model for access to this technology makes the tissue sterilization process more streamlined, and more practical to apply."

In order to use the new Clearant Sterilization Service, a client tissue bank will soak the tissue in a radioprotectant solution developed by Clearant. The tissue bank then transfers the tissue to Clearant's Chicago-area facility where it will be sterilized using controlled levels of radiation. The terminally-sealed and sterilized tissue may be returned to the tissue bank within 72 hours. No long-term contract is necessary for clients to access this service.

"The favorable response we have received from tissue banks at the recent American Association of Tissue Banks Conference has quickly turned into an agreement," said Alain Delongchamp, Chief Executive Officer of Clearant, Inc. "Clearant offers the only commercially-available technology that meets final-packaging sterility levels equal to those of medical devices while maintaining tissue integrity. Results to date, combined with the recent FDA guidance on Good Tissue Practices, should increasingly drive tissue banks to employ our technology."

In addition to Bone Bank Allografts' announced agreement to adopt the Clearant Sterilization Service, Clearant holds five North American tissue license agreements for the CLEARANT PROCESS(R).

About Clearant, Inc.

Clearant, Inc., a biotechnology company headquartered in Los Angeles, California, is a leader in pathogen inactivation for biological products. Clearant, Inc. has developed the patent-protected CLEARANT PROCESS(R), designed to substantially reduce all types of pathogens in biological products while maintaining a high degree of the underlying protein. Various sterilization methods on the market today only kill specific types of pathogens, such as bacteria or lipid-enveloped viruses, for specific products. The CLEARANT PROCESS(R) can substantially reduce all types of pathogens for products across many market segments including plasma proteins, tissue implants, recombinant products and blood products, and can be applied at various stages of product processing/manufacturing, including in the final container.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the biotechnology industry, and additional risks discussed in the company's filings with the SEC.

For more information about Clearant, Inc., please see www.clearant.com.